Cardio Diagnostics (NASDAQ:CDIO) Posts Earnings Results

Posted by Tammy Falkenburg on May 16th, 2026

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) posted its earnings results on Friday. The company reported ($0.63) EPS for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%.

Cardio Diagnostics Trading Down 7.7%

Shares of NASDAQ:CDIO opened at $1.55 on Friday. The company has a fifty day simple moving average of $2.33 and a 200 day simple moving average of $2.69. The firm has a market cap of $4.59 million, a PE ratio of -0.42 and a beta of 2.30. Cardio Diagnostics has a 12-month low of $0.97 and a 12-month high of $7.91.

Institutional Trading of Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics at the end of the most recent quarter. 8.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Read Our Latest Research Report on CDIO

Cardio Diagnostics Company Profile

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.